The Latest Cardiac and Vascular News
SEOUL, South Korea, Feb. 21, 2023 /PRNewswire/ — Mezzion Pharma Co., Ltd. (Mezzion Pharma) has submitted a confirmatory pivotal Phase 3 Clinical Trial in Fontan subjects to the Food and Drug Administration (FDA). In the Type B meeting between the FDA and Mezzion, the FDA provided Mezzion with a clear path forward […]
SEOUL, Republic of Korea, June 15, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (140410.KQ), and Mezzion Pharmaceuticals, Inc. (individually or collectively, “Mezzion”), a leader in the field of rare single ventricle congenital heart disease (“SVHD”) and SVHD patients with Fontan circulation, is pleased to announce that Bill Breitenbach has joined Mezzion as the Chief Commercial […]
SEOUL, South Korea, May 25, 2021 /PRNewswire/ — Mezzion Pharma Co., Ltd. (140410.KQ) is pleased to announce today that it has received notice from the FDA that its NDA submitted on March 26, 2021 for the use of udenafil to treat SVHD patients who have undergone Fontan palliation is sufficiently complete to permit a substantive review […]
Mezzion Pharma files new patent applications to cover globally this important MPI advancement, a unique new finding as a result of treatment of SVHD patients with udenafil SEOUL, South Korea, May 18, 2020 /PRNewswire/ — Mezzion Pharma Co. Ltd. today announced that analysis of data from its Phase 3 FUEL trial showed statistically significant positive […]
